Fungal endophthalmitis

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 12, 2011, Pages 1191-1201

  Chhablani, Jay ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

amphotericin B; Aspergillus; Candida; echinocandins; endogenous endophthalmitis; exogenous endophthalmitis; fluconazole; fungal endophthalmitis; ketoconazole; voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; TRIAMCINOLONE; VORICONAZOLE;

ABDOMINAL DISCOMFORT; ASPERGILLUS; BLURRED VISION; CANDIDA; CANDIDA ENDOPHTHALMITIS; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; COLOR VISION; CRYPTOCOCCOSIS; DIARRHEA; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EYE TOXICITY; FEVER; FUNGAL ENDOPHTHALMITIS; FUSARIOSIS; FUSARIUM; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; HYPOTENSION; LIVER DISEASE; LIVER TOXICITY; MAINTENANCE DRUG DOSE; NAUSEA; NEPHROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; RASH; REVIEW; RIGOR; SIDE EFFECT; SPECIES DIFFERENCE; TREATMENT OUTCOME; VISUAL DISORDER; VITRECTOMY; VOMITING;

ADRENAL CORTEX HORMONES; ANTIFUNGAL AGENTS; ASPERGILLUS NIGER; CANDIDA ALBICANS; CANDIDIASIS; ENDOPHTHALMITIS; EYE INFECTIONS, FUNGAL; FUSARIUM; HUMANS; INJECTIONS, INTRAOCULAR; INJECTIONS, INTRAVENOUS; SPECIES SPECIFICITY; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 82455184699     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.139     Document Type: Review

References (92)

1. Kresloff MS, Castellarin AA, Zarbin MA. Endophthalmitis. Surv. Ophthalmol. 43(3), 193-224 (1998).
2. Lynn WA, Lightman S. The eye in systemic infection. Lancet 364(9443), 1439-1450 (2004).
3. Gupta A, Srinivasan R, Kaliaperumal S, Saha I. Post-traumatic fungal endophthalmitis - a prospective study. Eye (Lond.) 22(1), 13-17 (2008).
4. Lalwani GA, Flynn HW Jr, Scott IU et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005).Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology 115(3), 473-476 (2008).
5. Puliafito CA, Baker AS, Haaf J, Foster CS. Infectious endophthalmitis. Review of 36 cases. Ophthalmology 89(8), 921-929 (1982).
6. Shrader SK, Band JD, Lauter CB, Murphy P. The clinical spectrum of endophthalmitis: incidence, predisposing factors, and features influencing outcome. J. Infect. Dis. 162(1), 115-120 (1990).
7. Binder MI, Chua J, Kaiser PK, Procop GW, Isada CM. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore) 82(2), 97-105 (2003).
8. Leibovitch I, Lai T, Raymond G, Zadeh R, Nathan F, Selva D. Endogenous endophthalmitis: a 13-year review at a tertiary hospital in South Australia. Scand.J. Infect. Dis. 37(3), 184-189 (2005).
9. Schiedler V, Scott IU, Flynn HW Jr, Davis JL, Benz MS, Miller D. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am. J. Ophthalmol. 137(4), 725-731 (2004).
10. Anand AR, Therese KL, Madhavan HN. Spectrum of aetiological agents of postoperative endophthalmitis and antibiotic susceptibility of bacterial isolates. Ind. J. Ophthalmol. 48(2), 123-128 (2000).
11. Majji AB, Jalali S, Das T, Gopinathan U. Role of intravitreal dexamethasone in exogenous fungal endophthalmitis. Eye (Lond.) 13 (Pt 5), 660-665 (1999).
12. Wykoff CC, Flynn HW Jr, Miller D, Scott IU, Alfonso EC. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology 115(9), 1501-1507, 1507 e1501-1502 (2008).
13. Narang S, Gupta A, Gupta V et al. Fungal endophthalmitis following cataract surgery: clinical presentation, microbiological spectrum, and outcome. Am. J. Ophthalmol. 132(5), 609-617 (2001).
14. Essman TF, Flynn HW Jr, Smiddy WE et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic. Surg. Lasers 28(3), 185-194 (1997).
15. Blumenkranz MS, Stevens DA. Endogenous coccidioidal endophthalmitis. Ophthalmology 87(10), 974-984 (1980).
16. Weishaar PD, Flynn HW Jr, Murray TG et al. Endogenous Aspergillus endophthalmitis. Clinical features and treatment outcomes. Ophthalmology 105(1), 57-65 (1998).
17. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin. Infect. Dis. 48(5), 503-535 (2009).
18. Anand A, Madhavan H, Neelam V, Lily T. Use of polymerase chain reaction in the diagnosis of fungal endophthalmitis. Ophthalmology 108(2), 326-330 (2001).
19. Manzouri B, Vafidis GC, Wyse RK. Pharmacotherapy of fungal eye infections. Exp. Opin. Pharmacother. 2(11), 1849-1857 (2001).
20. O'Day DM, Head WS, Robinson RD, Stern WH, Freeman JM. Intraocular penetration of systemically administered antifungal agents. Curr. Eye Res. 4(2), 131-134 (1985).
21. Wingard LB Jr, Zuravleff JJ, Doft BH, Berk L, Rinkoff J. Intraocular distribution of intravitreally administered amphotericin B in normal and vitrectomized eyes. Invest. Ophthalmol. Vis. Sci. 30(10), 2184-2189 (1989).
22. Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 19(3), 306-323 (1999).
23. Darling K, Singh J, Wilks D. Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC).J. Infect. 40(1), 92-94 (2000).
24. Neppert B, Guthoff R, Heidemann HT. Endogenous Candida endophthalmitis in a drug dependent patient: intravenous therapy with liposome encapsulated amphotericin B. Klin. Monbl. Augenheilkd. 201(2), 122-124 (1992).
25. Kaji Y, Yamamoto E, Hiraoka T, Oshika T. Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B. Graefes. Arch. Clin. Exp. Ophthalmol. 247(4), 549-553 (2009).
26. Koc A, Onal S, Yenice O, Kazokoglu H. Pars plana vitrectomy and intravitreal liposomal amphotericin B in the treatment of Candida endophthalmitis. Ophthalmic. Surg. Lasers Imag. doi:10.3928/15428877-20100215-35 (2010) (Epub ahead of print).
27. O'Day DM, Foulds G, Williams TE, Robinson RD, Allen RH, Head WS. Ocular uptake of fluconazole following oral administration. Arch. Ophthalmol. 108(7), 1006-1008 (1990).
28. Foster CS, Lass JH, Moran-Wallace K, Giovanoni R. Ocular toxicity of topical antifungal agents. Arch. Ophthalmol. 99(6), 1081-1084 (1981).
29. Yoshizumi MO, Banihashemi AR. Experimental intravitreal ketoconazole in DMSO. Retina 8(3), 210-215 (1988).
30. Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob. Agents Chemother. 31(1), 6-10 (1987).
31. Riddell JT, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin. Infect. Dis. 52(5), 648-653 (2011).
32. Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica 208(3), 147-156 (1994).
33. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia study group and the national institute. N. Engl. J. Med. 331(20), 1325-1330 (1994).
34. Miyamoto H, Ogura Y, Hashizoe M, Kunou N, Honda Y, Ikada Y. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr. Eye Res. 16(9), 930-935 (1997).
35. Habib FS, Fouad EA, Abdel-Rhaman MS, Fathalla D. Liposomes as an ocular delivery system of fluconazole: in-vitro studies. Acta Ophthalmol. 88(8), 901-904 (2010).
36. Nomura J, Ruskin J. Failure of therapy with fluconazole for candidal endophthalmitis. Clin. Infect. Dis. 17(5), 888-889 (1993).
37. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42(4), 1519-1527 (2004).
38. Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br. J. Ophthalmol. 92(7), 871-878 (2008).
39. Hariprasad SM, Mieler WF, Holz ER et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. 122(1), 42-47 (2004).
40. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am. J. Ophthalmol. 139(1), 135-140 (2005).
41. Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 113(7), 1184-1186 (2006).
42. Gao H, Pennesi ME, Shah K et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch. Ophthalmol. 122(11), 1687-1692 (2004).
43. Tu EY, Mccartney DL, Beatty RF, Springer KL, Levy J, Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH- 56592).Am. J. Ophthalmol. 143(2), 222-227 (2007).
44. Langner S, Staber PB, Neumeister P. Posaconazole in the management of refractory invasive fungal infections. Ther. Clin. Risk. Manag. 4(4), 747-758 (2008).
45. Aperis G, Alivanis P. Posaconazole: a new antifungal weapon. Rev. Recent Clin. Trials (2011).
46. Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br. J. Ophthalmol. 86(7), 829-830 (2002).
47. Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Exp. Opin. Investig. Drugs 12(8), 1313-1333 (2003).
48. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347(25), 2020-2029 (2002).
49. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38(2), 161-189 (2004).
50. Durand ML, Kim IK, D'amico DJ et al. Successful treatment of fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am. J. Ophthalmol. 140(3), 552-554 (2005).
51. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin. Infect. Dis. 41(3), e27-e28 (2005).
52. Harrison JM, Glickman RD, Ballentine CS et al. Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits. DoC. Ophthalmol. 110(1), 37-55 (2005).
53. George J, Reboli AC. Anidulafungin: when and how? The clinician's view. Mycoses doi:10.1111/j.1439-0507.2011.02052.x (2011) (Epub ahead of print).
54. Groll AH, Mickiene D, Petraitis V et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother. 45(12), 3322-3327 (2001).
55. Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy 27(12), 1711-1721 (2007).
56. Robertson DM, Riley FC, Hermans PE. Endogenous Candida oculomycosis. Report of two patients treated with flucytosine. Arch. Ophthalmol. 91(1), 33-38 (1974).
57. Zhang YQ, Wang WJ. Treatment outcomes after pars plana vitrectomy for endogenous endophthalmitis. Retina 25(6), 746-750 (2005).
58. Smiddy WE. Treatment outcomes of endogenous fungal endophthalmitis. Curr. Opin. Ophthalmol. 9(3), 66-70 (1998).
59. Shen X, Xu G. Vitrectomy for endogenous fungal endophthalmitis. Ocul. Immunol. Inflamm. 17(3), 148-152 (2009).
60. Sato Y, Miyasaka S, Shimada H. Prognosis of endogenous fungal endophthalmitis and utility of Ishibashi's classification. Jpn J. Ophthalmol. 45(2), 181-186 (2001).
61. Coats ML, Peyman GA. Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina 12(1), 46-51 (1992).
62. Pathengay A, Shah GY, Das T, Sharma S. Intravitreal triamcinolone acetonide in the management of exogenous bacterial endophthalmitis. Am. J. Ophthalmol. 141(5), 938-940 (2006).
63. Marmor MF. Serous detachment after high-dose intravitreal dexamethasone: toxic or osmotic? Arch. Ophthalmol. 111(1), 20-21 (1993).
64. Riddell Iv J, Mcneil SA, Johnson TM, Bradley SF, Kazanjian PH, Kauffman CA. Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 81(4), 311-320 (2002).
65. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin. Infect. Dis. 46(3), 327-360 (2008).
66. Axelrod AJ, Peyman GA, Apple DJ. Toxicity of intravitreal injection of amphotericin B. Am. J. Ophthalmol. 76(4), 578-583 (1973).
67. Marco F, Pfaller MA, Messer SA, Jones RN. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med. Mycol. 36(6), 433-436 (1998).
68. Gupta A, Gupta V, Dogra MR et al. Fungal endophthalmitis after a single intravenous administration of presumably contaminated dextrose infusion fluid. Retina 20(3), 262-268 (2000).
69. Rao NA, Hidayat AA. Endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared with aspergillosis. Am. J. Ophthalmol. 132(2), 244-251 (2001).
70. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44(4), 531-540 (2007).
71. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin. Infect. Dis. 40(5), e46-e48 (2005).
72. Donahue SP, Greven CM, Zuravleff JJ et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 101(7), 1302-1309 (1994).
73. Louie A, Liu W, Miller DA et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob. Agents Chemother. 43(12), 2831-2840 (1999).
74. Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin. Infect. Dis. 27(5), 1130-1133 (1998).
75. Menezes AV, Sigesmund DA, Demajo WA, Devenyi RG. Mortality of hospitalized patients with Candida endophthalmitis. Arch. Intern. Med. 154(18), 2093-2097 (1994).
76. Tanaka M, Kobayashi Y, Takebayashi H, Kiyokawa M, Qiu H. Analysis of predisposing clinical and laboratory findings for the development of endogenous fungal endophthalmitis. A retrospective 12-year study of 79 eyes of 46 patients. Retina 21(3), 203-209 (2001).
77. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur. J. Clin. Microbiol. Infect. Dis. 25(7), 419-425 (2006).
78. Rodenbiker HT, Ganley JP. Ocular coccidioidomycosis. Surv. Ophthalmol. 24(5), 263-290 (1980).
79. Crump JR, Elner SG, Elner VM, Kauffman CA. Cryptococcal endophthalmitis: case report and review. Clin. Infect. Dis. 14(5), 1069-1073 (1992).
80. Sheu SJ, Chen YC, Kuo NW, Wang JH, Chen CJ. Endogenous cryptococcal endophthalmitis. Ophthalmology 105(2), 377-381 (1998).
81. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 50(3), 291-322 (2010).
82. Lewis JL, Rabinovich S. The wide spectrum of cryptococcal infections. Am. J. Med. 53(3), 315-322 (1972).
83. Spickard A. Diagnosis and treatment of cryptococcal disease. South Med. J. 66(1), 26-31 (1973).
84. Proenca-Pina J, Ssi Yan Kai I, Bourcier T, Fabre M, Offret H, Labetoulle M. Fusarium keratitis and endophthalmitis associated with lens contact wear. Int. Ophthalmol. 30(1), 103-107 (2010).
85. Chakrabarti A, Shivaprakash MR, Singh R et al. Fungal endophthalmitis: fourteen years' experience from a centre in India. Retina 28(10), 1400-1407 (2008).
86. Cakir M, Imamoglu S, Cekic O et al. An outbreak of early-onset endophthalmitis caused by fusarium species following cataract surgery. Curr. Eye Res. 34(11), 988-995 (2009).
87. Gabriele P, Hutchins RK. Fusarium endophthalmitis in an intravenous drug abuser. Am. J. Ophthalmol. 122(1), 119-121 (1996).
88. Goldstein BG, Buettner H. Histoplasmic endophthalmitis. A clinicopathologic correlation. Arch. Ophthalmol. 101(5), 774-777 (1983).
89. Hoefnagels KL, Pijpers PM. Histoplasma capsulatum in a human eye. Am. J. Ophthalmol. 63(4), 715-723 (1967).
90. Pulido JS, Folberg R, Carter KD, Coonan P. Histoplasma capsulatum endophthalmitis after cataract extraction. Ophthalmology 97(2), 217-220 (1990).
91. Gonzales CA, Scott IU, Chaudhry NA et al. Endogenous endophthalmitis caused by Histoplasma capsulatum var. capsulatum: a case report and literature review. Ophthalmology 107(4), 725-729 (2000).
92. Wheat LJ, Freifeld AG, Kleiman MB et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious diseases society of America. Clin. Infect. Dis. 45(7), 807-825 (2007).